AC8
vs
S
S&P/ASX 300
AC8
Over the past 12 months, AC8 has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +6% growth.
Stocks Performance
AC8 vs S&P/ASX 300
Performance Gap
AC8 vs S&P/ASX 300
Performance By Year
AC8 vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Auscann Group Holdings Ltd
Glance View
AusCann Group Holdings Ltd. engages in development, production, and distribution of cannabinoid-based medicines within Australia and internationally. The company is headquartered in Perth, Western Australia. The firm focuses on providing healthcare professionals and veterinarians with pharmaceutical and nutraceutical products to support the treatment of their patients. Its controlled-dose technology platform, Neuvis, is for delivering cannabinoids to human patients through CannPal Animal Therapeutics Pty Ltd. DermaCann is its lead cannabidiol (CBD) derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. CPAT-01 is a liquid, oral veterinary medicine containing tetrahydrocannabinol (THC) and CBD whole plant extracts in a combined ratio to cure pain and inflammation in dogs. CPAT-01 is in Phase II clinical trials. AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited are its subsidiaries.